Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised …

RD Lopes, SM Al-Khatib, L Wallentin, H Yang, J Ansell… - The Lancet, 2012 - thelancet.com
Summary Background The Apixaban for Reduction in Stroke and Other Thromboembolic
Events in Atrial Fibrillation (ARISTOTLE) trial showed that apixaban is better than warfarin at …
被引用次数：265 相关文章

Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised …

RD Lopes, SM Al-Khatib, L Wallentin, H Yang, J Ansell… - The Lancet, 2012 - Elsevier
BACKGROUND: The Apixaban for Reduction in Stroke and Other Thromboembolic Events
in Atrial Fibrillation (ARISTOTLE) trial showed that apixaban is better than warfarin at …

Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised …

RD Lopes, SM Al-Khatib, L Wallentin, H Yang, J Ansell… - Lancet, 2012 - eprints.gla.ac.uk
Background The Apixaban for Reduction in Stroke and Other Thromboembolic Events in
Atrial Fibrillation (ARISTOTLE) trial showed that apixaban is better than warfarin at …

Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised …

RD Lopes, SM Al-Khatib, L Wallentin, H Yang, J Ansell… - Lancet, 2012 - thelancet.com
Background The Apixaban for Reduction in Stroke and Other Thromboembolic Events in
Atrial Fibrillation (ARISTOTLE) trial showed that apixaban is better than warfarin at …

Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised …

RD Lopes, SM Al-Khatib, L Wallentin, H Yang, J Ansell… - The Lancet, 2012 - infona.pl
The Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation
(ARISTOTLE) trial showed that apixaban is better than warfarin at prevention of stroke or …

[引用][C] Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a …

RD Lopes, SM Al-Khatib, L Wallentin, H Yang, J Ansell… - The Lancet, 2012 - cir.nii.ac.jp
Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and
of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial | CiNii …

Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised …

RD Lopes, SM Al-Khatib, L Wallentin… - Lancet (London …, 2012 - europepmc.org
Background The Apixaban for Reduction in Stroke and Other Thromboembolic Events in
Atrial Fibrillation (ARISTOTLE) trial showed that apixaban is better than warfarin at …

Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: A secondary analysis of a randomised …

RD Lopes, SM Al-Khatib, L Wallentin… - The …, 2012 - acuresearchbank.acu.edu.au
Background: The Apixaban for Reduction in Stroke and Other Thromboembolic Events in
Atrial Fibrillation (ARISTOTLE) trial showed that apixaban is better than warfarin at …

Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised …

RD Lopes, SM Al-Khatib, L Wallentin, H Yang, J Ansell… - 2012 - pubmed.ncbi.nlm.nih.gov
Background The Apixaban for Reduction in Stroke and Other Thromboembolic Events in
Atrial Fibrillation (ARISTOTLE) trial showed that apixaban is better than warfarin at …

[引用][C] Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a …

RD LOPES, SM AL-KHATIB, L WALLENTIN… - Lancet, 2012 - Elsevier